Boston Scientific Corp

Boston Scientific’s $14.5 billion Penumbra acquisition and new FDA‑approved Farapoint catheter expand its cardiovascular portfolio, boost margins, and drive future growth.

Boston Scientific’s latest trading surge reflects strong revenue growth, high profit margins, and strategic AI‑driven innovations poised to capture future medical‑device markets.

Boston Scientific’s flat $98 share price reflects a consolidation phase—yet robust 7.8% revenue growth, 68% gross margin, and rising bundled‑payment adoption suggest strong upside for investors.

Boston Scientific’s analyst sentiment shifts: Canaccord Genuity cuts its target slightly while RBC lifts it, reflecting a cautious yet optimistic view of the medical‑device firm’s valuation amid recent market consolidation.

Boston Scientific’s 5‑year share‑price surge shows how strong product diversity, R&D investment and resilient supply chains keep a medical‑device leader ahead of competitors and growing returns for investors.

Boston Scientific’s new HCSC coverage for Intracept could unlock $24.9 billion in revenue and triple its market reach, driving value‑based, same‑day outpatient care for low‑back pain.

Boston Scientific Corp. remains a top choice for investors, thanks to its solid fundamentals, diversified portfolio, and strong growth in medical‑device markets.

Boston Scientific Corporation has seen a surge in analyst optimism due to its strong positioning in the rapidly growing duodenoscope market, with upgraded price targets and a potential upside of 29-40% within a year.

Boston Scientific Corporation has demonstrated robust growth over the past year, driven by a strong product pipeline, global expansion, and operational efficiency, and has further solidified its position with a strategic acquisition of Elutia’s bioe…

Boston Scientific Corp has experienced significant growth over the past decade, with its market capitalization increasing and an upcoming Investor Day meeting planned to discuss its third-quarter results and long-term growth strategies.